Literature DB >> 19074351

Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI.

Michael J Minzenberg1, Andrew J Watrous, Jong H Yoon, Stefan Ursu, Cameron S Carter.   

Abstract

Models of cognitive control posit a key modulatory role for the pontine locus coeruleus-norepinephrine (LC-NE) system. In nonhuman primates, phasic LC-NE activity confers adaptive adjustments in cortical gain in task-relevant brain networks, and in performance, on a trial-by-trial basis. This model has remained untested in humans. We used the pharmacological agent modafinil to promote low-tonic/high-phasic LC-NE activity in healthy humans performing a cognitive control task during event-related functional magnetic resonance imaging (fMRI). Modafanil administration was associated with decreased task-independent, tonic LC activity, increased task-related LC and prefrontal cortex (PFC) activity, and enhanced LC-PFC functional connectivity. These results confirm in humans the role of the LC-NE system in PFC function and cognitive control and suggest a mechanism for therapeutic action of procognitive noradrenergic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074351     DOI: 10.1126/science.1164908

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  65 in total

1.  Stress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkers.

Authors:  Martin Zack; Tracy M Woodford; Anne M Tremblay; Lindsay Steinberg; Laurie A Zawertailo; Usoa E Busto
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Effects of acute modafinil on cognition in trichotillomania.

Authors:  Samuel R Chamberlain; Jon E Grant; Anna Costa; Ulrich Müller; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2010-08-17       Impact factor: 4.530

3.  Eyes on me: an fMRI study of the effects of social gaze on action control.

Authors:  Leonhard Schilbach; Simon B Eickhoff; Edna Cieslik; Nadim J Shah; Gereon R Fink; Kai Vogeley
Journal:  Soc Cogn Affect Neurosci       Date:  2010-07-22       Impact factor: 3.436

Review 4.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 5.  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors:  Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal:  Sleep Med Rev       Date:  2018-11-08       Impact factor: 11.609

6.  Human reversal learning under conditions of certain versus uncertain outcomes.

Authors:  Anna-Maria D'Cruz; Michael E Ragozzino; Matthew W Mosconi; Mani N Pavuluri; John A Sweeney
Journal:  Neuroimage       Date:  2011-01-28       Impact factor: 6.556

7.  α-Actinin-1 promotes activity of the L-type Ca2+ channel Cav 1.2.

Authors:  Matthew Turner; David E Anderson; Peter Bartels; Madeline Nieves-Cintron; Andrea M Coleman; Peter B Henderson; Kwun Nok Mimi Man; Pang-Yen Tseng; Vladimir Yarov-Yarovoy; Donald M Bers; Manuel F Navedo; Mary C Horne; James B Ames; Johannes W Hell
Journal:  EMBO J       Date:  2020-01-27       Impact factor: 11.598

Review 8.  The Mechanisms Underlying the ASD Advantage in Visual Search.

Authors:  Zsuzsa Kaldy; Ivy Giserman; Alice S Carter; Erik Blaser
Journal:  J Autism Dev Disord       Date:  2016-05

9.  Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Jean Logan; David Alexoff; Wei Zhu; Frank Telang; Gene-Jack Wang; Millard Jayne; Jacob M Hooker; Christopher Wong; Barbara Hubbard; Pauline Carter; Donald Warner; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Karen Apelskog-Torres
Journal:  JAMA       Date:  2009-03-18       Impact factor: 56.272

Review 10.  Good night and good luck: norepinephrine in sleep pharmacology.

Authors:  Heather A Mitchell; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2009-10-13       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.